TP53 and neoplasm: In summary, we showed that p53 immunohistochemical analysis is a valuable predictor of advanced neoplasia—both prevalent and incident—in patients with BE-IND, a heterogeneous group in whom clinico-demographic parameters often fail as a risk stratification tool.